Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.58 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.58 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.58 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.58 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.58 |
| ▸ | HTR6 | P50406 | 4/20 | 0.56 |
| ▸ | MC5R | P33032 | 3/20 | 0.52 |
| ▸ | MC3R | P41968 | 1/20 | 0.52 |
| ▸ | MC1R | Q01726 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | TACR3 | P29371 | 1/20 | 0.48 |
| ▸ | TACR2 | P21452 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8790234 | 1.00 | GABRA1 (0.58) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL30072 | 1.00 | GABRA1 (0.58) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL8791242 | 0.97 | GABRA1 (0.54) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL8875340 | 0.88 | UTS2R (0.51) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL30446285 | 0.88 | HTR2A (0.46) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL838920 | 0.88 | HTR2A (0.46) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL8542318 | 0.88 | UTS2R (0.51) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL9973149 | 0.88 | HTR2A (0.46) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL8789702 | 0.87 | HTR1A (0.61) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL8789694 | 0.87 | HTR1A (0.61) | GABRA1GABRG2GABRB3GABRA3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231373-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | disclosed |
| EP-2609078-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | Novartis AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012025164-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2012-03-01 | — | — | WO | disclosed |
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-10 | — | — | US | disclosed |
| US-6465500-B1 | PSYCHOTHERAPEUTICS; DEPRESSION, ANXIETY, EATING DISORDERS, OBESITY, DRUG ABUSE, CLUSTER HEADACHE, MIGRAINE, PAIN, CHRONIC PAROXYSMAL HEMICRANIA, HEADACHE ASSOCIATED WITH VASCULAR DISORDERS; ANTIHYPERTENSIVES, VASODILATORS | PFIZER INC. | 2002-10-15 | — | — | US | disclosed |
| US-6436957-B1 | DISORDERS FROM DEFICIENT SEROTONERGIC NEUROTRANSMISSION; 3-PYRROLIDIN-2-YLMETHYL-1H-INDOLES | PFIZER INC. | 2002-08-20 | — | — | US | disclosed |
| US-6410739-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC | 2002-06-25 | — | — | US | disclosed |
| EP-0629199-B1 | INDOLE DERIVATIVES AS 5-HT1 AGONISTS | PFIZER (US) | 2002-06-05 | — | — | EP | disclosed |
| US-6387937-B1 | ANTISEROTONINE AGENT; HEADACHES | PFIZER INC. | 2002-05-14 | — | — | US | disclosed |
| US-6387941-B1 | ANTISEROTONINE AGENTS | PFIZER INC. | 2002-05-14 | — | — | US | disclosed |
| US-5607951-A | SEROTONIN AGONIST FOR NERVOUS SYSTEM DISORDERS, ANALGESICS AND PSYCHOTHERAPEUTICS | PFIZER INC (US) | 1997-03-04 | — | — | US | disclosed |
| US-5594014-A | Indole derivatives as 5-HT1 agonists | PFIZER INC (US) | 1997-01-14 | — | — | US | disclosed |
| US-5578612-A | Indole derivatives | PFIZER INC. (US) | 1996-11-26 | — | — | US | disclosed |
| US-5559246-A | PROCESS OF DEHYDROHALOGENATION FOR CYCLIZATION TO PRODUCE PSYCHOTHERAPEUTIC AGENTS AND ANTISEROTONIN ANTAGONIST | PFIZER INC. (US) | 1996-09-24 | — | — | US | disclosed |
| US-5559129-A | SEROTONIN (5HT1) ANTAGONIST FOR TREATMENT OF DEPRESSION, ANXIETY, EATING DISORDERS, OBESITY, DRUG ABUSE, HEADACHES, AND PAIN | PFIZER INC (US) | 1996-09-24 | — | — | US | disclosed |
| US-5545644-A | SEROTONIN AGONISTS; HYPOTENSIVE AND ANXIOLYTIC AGENTS; ANALGESICS; ANTIDEPRESSANTS; EATING DISORDERS; DRUG ABUSE; HEADACHES; VASCULAR DISORDERS | PFIZER INC. (US) | 1996-08-13 | — | — | US | disclosed |
| EP-0592438-A1 | INDOLE DERIVATIVES. | PFIZER (US) | 1994-04-20 | — | — | EP | disclosed |
| WO-1993020073-A1 | INDOLE DERIVATIVES AS 5-HT1 AGONISTS | PFIZER INC. (US) | 1993-10-14 | — | — | WO | disclosed |
| WO-1993018032-A1 | INDOLE DERIVATIVES AS 5-HT1 AGONISTS | PFIZER INC. (US) | 1993-09-16 | — | — | WO | disclosed |
| WO-1992006973-A1 | INDOLE DERIVATIVES | PFIZER INC. (US) | 1992-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231373-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | HDAC1, HDAC11, HDAC3 | GABRA1 2169/4885GABRG2 2437/4885GABRB3 2092/4885 |
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | HDAC1, HDAC11, HDAC3 | GABRA1 2071/4885GABRG2 2490/4885GABRB3 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.